Patents by Inventor Marian PERIS
Marian PERIS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160304844Abstract: Provided herein are mutant DNA-dependent polymerases which are derived from, or otherwise related to, wild type RB69 DNA polymerase. These mutant polymerases are capable of selectively binding labeled nucleotides. These mutant polymerases are also capable of incorporating a variety of naturally occurring and modified nucleotides, including, for example, terminator nucleotides.Type: ApplicationFiled: July 1, 2016Publication date: October 20, 2016Inventors: Marian PERIS, Michael PHELAN, Barnett ROSENBLUM, Stephen HENDRICKS
-
Publication number: 20160265045Abstract: Disclosed herein are modified polymerase compositions exhibiting altered polymerase activity, which can be useful in a variety of biological applications. Also disclosed herein are methods of making and using such compositions. In some embodiments, the compositions exhibit altered properties that can enhance their utility in a variety of biological applications. Such altered properties, can include, for example, altered nucleotide binding affinities, altered nucleotide incorporation kinetics, altered photostability and/or altered nanoparticle tolerance, as well as a range of other properties as disclosed herein.Type: ApplicationFiled: June 1, 2016Publication date: September 15, 2016Inventors: Stephen P. HENDRICKS, Michael PHELAN, Marian PERIS, Cheng-Yao CHEN, Daniel MAZUR, Xinzhan PENG, Amy CASTILLO
-
Patent number: 9399767Abstract: Provided herein are mutant DNA-dependent polymerases which are derived from, or otherwise related to, wild type RB69 DNA polymerase. These mutant polymerases are capable of selectively binding labeled nucleotides. These mutant polymerases are also capable of incorporating a variety of naturally occurring and modified nucleotides, including, for example, terminator nucleotides.Type: GrantFiled: February 27, 2014Date of Patent: July 26, 2016Assignee: LIFT TECHNOLOGIES CORPORATIONInventors: Marian Peris, Michael Phelan, Barnett Rosenblum, Stephen Hendricks
-
Publication number: 20160208318Abstract: Provided herein are compositions and systems for use in polymerase-dependent, nucleotide transient-binding methods. The methods are useful for deducing the sequence of a template nucleic acid molecule and single nucleotide polymorphism (SNP) analyses. The methods rely on the fact that the polymerase transient-binding time for a complementary nucleotide is longer compared to that of a non-complementary nucleotide. The labeled nucleotides transiently-binds the polymerase in a template-dependent manner, but does not incorporate. The methods are conducted under any reaction condition that permits transient binding of a complementary or non-complementary nucleotide to a polymerase, and inhibits nucleotide incorporation.Type: ApplicationFiled: January 8, 2016Publication date: July 21, 2016Inventors: Peter Vander Horn, Cheng-Yao Chen, Guobin Luo, Michael Previte, Jamshid Temirov, Theo Nikiforov, Zhaohui Zhou, Hongye Sun, Yufang Wang, Stefanie Yukiko Nishimura, Hongyi Wang, Marian Peris, Barnett Rosenblum, Michael Phelan
-
Publication number: 20160186224Abstract: In some embodiments, methods for ligating nucleic acid ends comprise: conducting a nucleic acid ligation reaction in the presence of at least one agent that generates a ligatable terminal 5? phosphate group by removing an adenylate group from a terminal 5? phosphate of a nucleic acid. In some embodiments, an aprataxin enzyme can catalyze removal of an adenylate group from a terminal 5? phosphate of a nucleic acid. In some embodiments, methods for ligating nucleic acid ends comprise: conducting a nucleic acid ligation reaction in the presence of an aprataxin enzyme under conditions suitable for ligating nucleic acid ends.Type: ApplicationFiled: March 15, 2016Publication date: June 30, 2016Applicant: Life Technologies CorporationInventors: Stephen Hendricks, David King, Lei Xi, Marian Peris
-
Patent number: 9365839Abstract: Disclosed herein are modified polymerase compositions exhibiting altered polymerase activity, which can be useful in a variety of biological applications. Also disclosed herein are methods of making and using such compositions. In some embodiments, the compositions exhibit altered properties that can enhance their utility in a variety of biological applications. Such altered properties, can include, for example, altered nucleotide binding affinities, altered nucleotide incorporation kinetics, altered photostability and/or altered nanoparticle tolerance, as well as a range of other properties as disclosed herein.Type: GrantFiled: May 12, 2015Date of Patent: June 14, 2016Assignee: Life Technologies CorporationInventors: Stephen P. Hendricks, Michael Phelan, Marian Peris, Cheng-Yao Chen, Daniel Mazur, Xinzhan Peng, Amy Castillo
-
Patent number: 9315861Abstract: In some embodiments, methods for ligating nucleic acid ends comprise: conducting a nucleic acid ligation reaction in the presence of at least one agent that generates a ligatable terminal 5? phosphate group by removing an adenylate group from a terminal 5? phosphate of a nucleic acid. In some embodiments, an aprataxin enzyme can catalyze removal of an adenylate group from a terminal 5? phosphate of a nucleic acid. In some embodiments, methods for ligating nucleic acid ends comprise: conducting a nucleic acid ligation reaction in the presence of an aprataxin enzyme under conditions suitable for ligating nucleic acid ends.Type: GrantFiled: November 28, 2012Date of Patent: April 19, 2016Assignee: Life Technologies CorporationInventors: Stephen Hendricks, David King, Lei Xi, Marian Peris
-
Patent number: 9255258Abstract: Provided herein are compositions and systems for use in polymerase-dependent, nucleotide transient-binding methods. The methods are useful for deducing the sequence of a template nucleic acid molecule and single nucleotide polymorphism (SNP) analyses. The methods rely on the fact that the polymerase transient-binding time for a complementary nucleotide is longer compared to that of a non-complementary nucleotide. The labeled nucleotides transiently-binds the polymerase in a template-dependent manner, but does not incorporate. The methods are conducted under any reaction condition that permits transient binding of a complementary or non-complementary nucleotide to a polymerase, and inhibits nucleotide incorporation.Type: GrantFiled: December 16, 2013Date of Patent: February 9, 2016Assignee: Life Technologies CorporationInventors: Peter Vander Horn, Cheng-Yao Chen, Guobin Luo, Michael Previte, Jamshid Temirov, Theo Nikiforov, Zhaohui Zhou, Hongye Sun, Yufang Wang, Stefanie Yukiko Nishimura, Hongyi Wang, Marian Peris, Barnett Rosenblum, Michael Phelan
-
Publication number: 20150247136Abstract: Disclosed herein are modified polymerase compositions exhibiting altered polymerase activity, which can be useful in a variety of biological applications. Also disclosed herein are methods of making and using such compositions. In some embodiments, the compositions exhibit altered properties that can enhance their utility in a variety of biological applications. Such altered properties, can include, for example, altered nucleotide binding affinities, altered nucleotide incorporation kinetics, altered photostability and/or altered nanoparticle tolerance, as well as a range of other properties as disclosed herein.Type: ApplicationFiled: May 12, 2015Publication date: September 3, 2015Inventors: Stephen P. HENDRICKS, Michael PHELAN, Marian PERIS, Cheng-Yao CHEN, Daniel MAZUR, Xinzhan PENG, Amy CASTILLO
-
Publication number: 20150031026Abstract: In some embodiments, methods for ligating nucleic acid ends comprise: conducting a nucleic acid ligation reaction in the presence of at least one agent that generates a ligatable terminal 5? phosphate group by removing an adenylate group from a terminal 5? phosphate of a nucleic acid. In some embodiments, an aprataxin enzyme can catalyze removal of an adenylate group from a terminal 5? phosphate of a nucleic acid. In some embodiments, methods for ligating nucleic acid ends comprise: conducting a nucleic acid ligation reaction in the presence of an aprataxin enzyme under conditions suitable for ligating nucleic acid ends.Type: ApplicationFiled: November 28, 2012Publication date: January 29, 2015Inventors: Stephen Hendricks, David King, Lei Xi, Marian Peris
-
Publication number: 20140234940Abstract: Provided herein are mutant DNA-dependent polymerases which are derived from, or otherwise related to, wild type RB69 DNA polymerase. These mutant polymerases are capable of selectively binding labeled nucleotides. These mutant polymerases are also capable of incorporating a variety of naturally occurring and modified nucleotides, including, for example, terminator nucleotides.Type: ApplicationFiled: February 27, 2014Publication date: August 21, 2014Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Marian PERIS, Michael PHELAN, Barnett ROSENBLUM, Stephen HENDRICKS
-
Publication number: 20140234853Abstract: Provided herein are compositions and systems for use in polymerase-dependent, nucleotide transient-binding methods. The methods are useful for deducing the sequence of a template nucleic acid molecule and single nucleotide polymorphism (SNP) analyses. The methods rely on the fact that the polymerase transient-binding time for a complementary nucleotide is longer compared to that of a non-complementary nucleotide. The labeled nucleotides transiently-binds the polymerase in a template-dependent manner, but does not incorporate. The methods are conducted under any reaction condition that permits transient binding of a complementary or non-complementary nucleotide to a polymerase, and inhibits nucleotide incorporation.Type: ApplicationFiled: December 16, 2013Publication date: August 21, 2014Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Peter VANDER HORN, Cheng-Yao CHEN, Guobin LUO, Michael PREVITE, Jamshid TEMIROV, Theo NIKIFOROV, Zhaohui ZHOU, Hongye SUN, Yufang WANG, Stefanie Yukiko NISHIMURA, Hongyi WANG, Marian PERIS, Barnett ROSENBLUM, Michael PHELAN
-
Patent number: 8703461Abstract: Provided herein are mutant DNA-dependent polymerases which are derived from, or otherwise related to, wild type RB69 DNA polymerase. These mutant polymerases are capable of selectively binding labeled nucleotides. These mutant polymerases are also capable of incorporating a variety of naturally occurring and modified nucleotides, including, for example, terminator nucleotides.Type: GrantFiled: August 31, 2012Date of Patent: April 22, 2014Assignee: Life Technologies CorporationInventors: Marian Peris, Michael Phelan, Barnett Rosenblum, Stephen Hendricks
-
Patent number: 8632975Abstract: Provided herein are compositions and systems for use in polymerase-dependent, nucleotide transient-binding methods. The methods are useful for deducing the sequence of a template nucleic acid molecule and single nucleotide polymorphism (SNP) analyses. The methods rely on the fact that the polymerase transient-binding time for a complementary nucleotide is longer compared to that of a non-complementary nucleotide. The labeled nucleotides transiently-binds the polymerase in a template-dependent manner, but does not incorporate. The methods are conducted under any reaction condition that permits transient binding of a complementary or non-complementary nucleotide to a polymerase, and inhibits nucleotide incorporation.Type: GrantFiled: May 28, 2010Date of Patent: January 21, 2014Assignee: Life Technologies CorporationInventors: Peter B. Vander Horn, Cheng-Yao Chen, Guobin Luo, Michael Previte, Jamshid Temirov, Theo Nikiforov, Zhaohui Zhou, Hongye Sun, Yufang Wang, Stefanie Yukiko Nishimura, Hongyi Wang, Marian Peris, Barnett B. Rosenblum, Michael Phelan
-
Publication number: 20130005020Abstract: Provided herein are mutant DNA-dependent polymerases which are derived from, or otherwise related to, wild type RB69 DNA polymerase. These mutant polymerases are capable of selectively binding labeled nucleotides. These mutant polymerases are also capable of incorporating a variety of naturally occurring and modified nucleotides, including, for example, terminator nucleotides.Type: ApplicationFiled: August 31, 2012Publication date: January 3, 2013Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Marian PERIS, Michael PHELAN, Barnett B. ROSENBLUM, Stephen P. HENDRICKS
-
Publication number: 20120322057Abstract: Disclosed herein are modified polymerase compositions exhibiting altered polymerase activity, which can be useful in a variety of biological applications. Also disclosed herein are methods of making and using such compositions. In some embodiments, the compositions exhibit altered properties that can enhance their utility in a variety of biological applications. Such altered properties, can include, for example, altered nucleotide binding affinities, altered nucleotide incorporation kinetics, altered photostability and/or altered nanoparticle tolerance, as well as a range of other properties as disclosed herein.Type: ApplicationFiled: July 3, 2012Publication date: December 20, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Stephen P. HENDRICKS, Michael PHELAN, Marian PERIS, Cheng-Yao CHEN, Daniel MAZUR, Xinzhan PENG, Amy CASTILLO
-
Publication number: 20110159551Abstract: The present invention provides compositions and methods for a reverse transcription reaction using a reversibly inactivated reverse transcriptase enzyme. The reversibly inactivated reverse transcriptase enzyme results from a chemical modification which inactivates the reverse transcriptase enzyme. The activity of the reverse transcriptase enzyme is recovered by an incubation of the reaction mixture at elevated temperature prior to, or as part of the reverse transcription reaction. The reverse transcriptase enzyme of the present invention provides for a signficant reduction in non-specific reverse transcription from template nucleic acid molecules because the formulation of the reaction mixture does not support the formation of reverse transcription products prior to activation of the reverse transcriptase.Type: ApplicationFiled: October 8, 2010Publication date: June 30, 2011Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Lei (a.k.a Larry) Xi, Roland Nagel, Stephen Hendricks, Jennifer Berkman, Marian Peris, Yulei Wang
-
Publication number: 20110014612Abstract: Disclosed herein are modified polymerase compositions exhibiting altered polymerase activity, which can be useful in a variety of biological applications. Also disclosed herein are methods of making and using such compositions. In some embodiments, the compositions exhibit altered properties that can enhance their utility in a variety of biological applications. Such altered properties, can include, for example, altered nucleotide binding affinities, altered nucleotide incorporation kinetics, altered photostability and/or altered nanoparticle tolerance, as well as a range of other properties as disclosed herein.Type: ApplicationFiled: March 26, 2010Publication date: January 20, 2011Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: STEPHEN P. HENDRICKS, MICHAEL PHELAN, MARIAN PERIS, CHENG-YAO CHEN, DANIEL MAZUR, XINZHAN PENG, AMY CASTILLO
-
Publication number: 20100330570Abstract: Provided herein are compositions and systems for use in polymerase-dependent, nucleotide transient-binding methods. The methods are useful for deducing the sequence of a template nucleic acid molecule and single nucleotide polymorphism (SNP) analyses. The methods rely on the fact that the polymerase transient-binding time for a complementary nucleotide is longer compared to that of a non-complementary nucleotide. The labeled nucleotides transiently-binds the polymerase in a template-dependent manner, but does not incorporate. The methods are conducted under any reaction condition that permits transient binding of a complementary or non-complementary nucleotide to a polymerase, and inhibits nucleotide incorporation.Type: ApplicationFiled: May 28, 2010Publication date: December 30, 2010Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Peter B. VANDER HORN, Cheng-Yao Chen, Guobin Luo, Michael Previte, Jamshid Temirov, Theo Nikiforov, Zhaohui Zhou, Hongye Sun, Yufang Wang, Stefanie Yukiko Nishimura, Hongyi Wang, Marian Peris, Barnett B. Rosenblum, Michael Phelan
-
Publication number: 20100311144Abstract: Provided herein are mutant DNA-dependent polymerases which are derived from, or otherwise related to, wild type RB69 DNA polymerase. These mutant polymerases are capable of selectively binding labeled nucleotides. These mutant polymerases are also capable of incorporating a variety of naturally occurring and modified nucleotides, including, for example, terminator nucleotides.Type: ApplicationFiled: May 28, 2010Publication date: December 9, 2010Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Marian PERIS, Michael Phelan, Barnett B. Rosenblum, Stephen P. Hendricks